ClinicalTrials.gg
CompletedNCT03934736Updated Aug 9, 2024Results posted

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

A Phase 1 interventional study of HEPLISAV-B® in End Stage Renal Disease on Hemodialysis (Diagnosis), sponsored by Dynavax Technologies Corporation. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Primary conditionKidney Failure, ChronicRegistry: DiseaseReclassifiedWhy we changed it
Registry
Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Failure, Chronic
Why
  1. Disease describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Kidney Failure, Chronic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Dynavax Technologies Corporation (part of Sanofi) · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
119
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
196th of 638
119 · median 48
Started
2019
with 32 others
Phase 1
89 of 765
8 open now
Registered
544th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 196th largest by enrollment of the 638 interventional ones that give a count, is one of 33 that started in 2019, is one of 89 in phase 1, and was the 544th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, single arm study design to evaluate HEPLISAV-B® in adults with ESRD who are initiating or undergoing hemodialysis.

Read the detailed description

Eligible participants will receive single doses of HEPLISAV-B® at Weeks 0, 4, 8, and 16 and will be followed through Week 68 or end of study (EOS). The study is designed to evaluate the immunogenicity over a 20-week period and safety over a 68-week period.

03

Conditions studied

  • End Stage Renal Disease on Hemodialysis (Diagnosis)

Browse trials for

Keywords

  • ESRD
  • Hemodialysis
  • End Stage Renal Disease
  • Hepatitis B
  • HEPLISAV-B
  • Prevention and Control
  • HBV Vaccine
  • Hepatitis B Vaccine
  • HEPLISAV
04

In context

Kidney Failure, Chronic Reclassified

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

This study's enrollment of 119 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

Dynavax Technologies Corporation is the lead sponsor of 25 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.

First submitted before Dynavax Technologies Corporation became part of Sanofi.

Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects at least 18 years of age
  • Laboratory confirmed negative serology result to virus (HBV) surface antigen (HBsAg), antibody to hepatitis B surface antigen (anti-HBs), and antibody to hepatitis B core antigen (anti-HBc) prior to first study injection
  • Must be clinically stable and in the opinion of the investigator able to comply with all study procedures
  • Must be able and willing to provide
  • Receiving hemodialysis or will initiate hemodialysis within 4 weeks of first study injection
  • Women of (WOCBP) must consistently use an acceptable method of or confirm in writing she will abstain from sexual activity from the Screening visit through 4 weeks after the last dose of study injection. Acceptable birth control methods include but are not limited to oral contraceptive medication, an intrauterine device (IUD), an injectable contraceptive (such as medroxyprogesterone acetate or Depo-Provera®), a birth control patch, or a barrier method (such as condom or diaphragm with spermicide).

Exclusion criteria

Exclusion Criteria:

  • Previous receipt of any vaccine
  • History of (HIV) or virus (HCV) infection or antibody to HIV or HCV
  • History of sensitivity to any component of study vaccine
  • Substance or alcohol abuse that in the opinion of the investigator would interfere with compliance or with interpretation of the study results
  • Recent or ongoing history of febrile illness (within 7 days of the first study injection)
  • Has received any of the following prior to the first study injection:

    • Within 14 days:

      a. Any inactivated vaccine

    • Within 28 days:

      1. Systemic (more than 3 consecutive days) or other immunomodulatory or immune suppressive medication with the exception of inhaled steroids
      2. Any
      3. Granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF)
      4. Any other medicinal agent
    • Within 90 days:

      1. Blood products or immunoglobulin
  • If female and pregnant, nursing, or planning to become pregnant during the study
  • Undergoing chemotherapy or expected to receive chemotherapy during the study period
  • Has a medical condition considered by the investigator likely to interfere with the subject's compliance or the interpretation of study assessments, including the following laboratory abnormalities which the investigator may consider if severe:

    • Anemia
    • Thrombocytopenia
    • Leukocytosis
    • Neutropenia
    • Metabolic acidosis
    • Increased (ALT) or aspartate aminotransferase (AST)
    • Hyperkalemia
    • Hypokalemia
  • Is scheduled to undergo a kidney transplant within 6 months of the first study injection
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

06

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    HEPLISAV-B®

    A single dose of 0.5 mL HEPLISAV-B® administered intramuscularly in the deltoid muscle at Week 0 (Visit 1), Week 4 (Visit 2), Week 8 (Visit 3), and Week 16 (Visit 4).

    Drug: HEPLISAV-B®

Interventions

  • HEPLISAV-B®, a licensed, commercially-available hepatitis B vaccine for adults 18 years of age and older, consisting of the adjuvant cytidine phosphoguanosine (CpG) 1018 combined with the antigen recombinant hepatitis B surface antigen (rHBsAg).

07

What researchers measure

Primary outcomes

  1. Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of Special Interest

    Proportion of participants with Medically-attended adverse events (MAEs), Serious Adverse Events (SAEs), and immune-mediated Adverse Events of Special Interest (AESIs). MAEs are Adverse events (AEs) for which a subject sought medical attention at a doctor's office, clinic or study site, or emergency room, or was hospitalized. SAEs are AEs that met the definition of Serious per FDA regulations.

    Time frame: Week 0 (Visit 1) until Week 68 or early termination

  2. Seroprotection Rate (SPR) = Percentage of Participants Who Have a Seroprotective Immune Response

    SPR is the percentage of participants who have a seroprotective immune response (antibody level to anti-HBsAg greater than or equal to 10 milli-international unit \[mIU\]/mL) after HEPLISAV-B

    Time frame: Week 20

Secondary outcomes

  1. Percentage of Subjects With Anti-HBs Concentration ≥100 mIU/mL

    Percentage of subjects with anti-HBs concentration ≥100 mIU/mL.

    Time frame: Weeks 4, 8, 16, 20

  2. Serum Anti-HBsAg Geometric Mean Concentration (GMC)

    Serum Anti-HBsAg Geometric Mean Concentration (GMC).

    Time frame: Weeks 4, 8, 16, 20

  3. Seroprotection Rate (SPR) = Percentage of Participants Who Have a Seroprotective Immune Response

    SPR is the percentage of participants who have a seroprotective immune response (antibody level to anti-HBsAg greater than or equal to 10 milli-international unit \[mIU\]/mL) after HEPLISAV-B

    Time frame: Weeks 4, 8, 16, 20

08

Results

Posted Aug 9, 2024

Participant flow

Participant flow — Overall Study
MilestoneHEPLISAV-B
Started119
Completed86
Not completed33

Outcome measures

PrimaryPercentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of Special Interest

Proportion of participants with Medically-attended adverse events (MAEs), Serious Adverse Events (SAEs), and immune-mediated Adverse Events of Special Interest (AESIs). MAEs are Adverse events (AEs) for which a subject sought medical attention at a doctor's office, clinic or study site, or emergency room, or was hospitalized. SAEs are AEs that met the definition of Serious per FDA regulations.

Time frame:
Week 0 (Visit 1) until Week 68 or early termination
Reported as:
Number · percentage of participants
Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of Special Interest
percentage of participantsHEPLISAV-B
New-onset Immune-mediated Adverse Events0.8
Medically-attended Adverse Events66.4
Serious Adverse Events48.7
PrimarySeroprotection Rate (SPR) = Percentage of Participants Who Have a Seroprotective Immune Response

SPR is the percentage of participants who have a seroprotective immune response (antibody level to anti-HBsAg greater than or equal to 10 milli-international unit \[mIU\]/mL) after HEPLISAV-B

Time frame:
Week 20
Reported as:
Number · percentage of participants
Seroprotection Rate (SPR) = Percentage of Participants Who Have a Seroprotective Immune Response
percentage of participantsHEPLISAV-B®
Seroprotection Rate (SPR) = Percentage of Participants Who Have a Seroprotective Immune Response89.3 (80.1 to 95.3)
SecondaryPercentage of Subjects With Anti-HBs Concentration ≥100 mIU/mL

Percentage of subjects with anti-HBs concentration ≥100 mIU/mL.

Time frame:
Weeks 4, 8, 16, 20
Reported as:
Number · percentage of subjects with anti-HBs≥100
Percentage of Subjects With Anti-HBs Concentration ≥100 mIU/mL
percentage of subjects with anti-HBs≥100HEPLISAV-B
Week 45.4 (1.5 to 13.3)
Week 833.8 (23.2 to 45.7)
Week 1657.3 (45.4 to 68.7)
Week 2081.3 (70.7 to 89.4)
SecondarySerum Anti-HBsAg Geometric Mean Concentration (GMC)

Serum Anti-HBsAg Geometric Mean Concentration (GMC).

Time frame:
Weeks 4, 8, 16, 20
Reported as:
Geometric mean · mIU/mL
Serum Anti-HBsAg Geometric Mean Concentration (GMC)
mIU/mLHEPLISAV-B
Week 44.4 (3.0 to 6.5)
Week 833.5 (17.5 to 64.3)
Week 16155.3 (81.5 to 296.2)
Week 201061.8 (547.2 to 2060.2)
SecondarySeroprotection Rate (SPR) = Percentage of Participants Who Have a Seroprotective Immune Response

SPR is the percentage of participants who have a seroprotective immune response (antibody level to anti-HBsAg greater than or equal to 10 milli-international unit \[mIU\]/mL) after HEPLISAV-B

Time frame:
Weeks 4, 8, 16, 20
Reported as:
Number · SPR percent (≥ 10 mIU/mL)
Seroprotection Rate (SPR) = Percentage of Participants Who Have a Seroprotective Immune Response
SPR percent (≥ 10 mIU/mL)HEPLISAV-B
Week 420.3 (11.8 to 31.2)
Week 856.8 (44.7 to 68.2)
Week 1678.7 (67.7 to 87.3)
Week 2089.3 (80.1 to 95.3)

Adverse events

Collected over The reporting period for All-Cause Mortality, Serious Adverse Events, and Other (Not Including Serious) Adverse Events begins at the time of the first study treatment from Visit 1 (Week 0) through EOS Visit (Week 68).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HEPLISAV-B14/119 (11.8%)58/119 (48.7%)0/119 (0%)
Most frequent serious events
Showing 10 of 116
Most frequent serious events
EventHEPLISAV-B
PneumoniaInfections and infestations9/119
AnemiaBlood and lymphatic system disorders5/119
Gastrointestinal HaemorrhageGastrointestinal disorders5/119
SepsisInfections and infestations5/119
CellulitisInfections and infestations4/119
Corona Virus InfectionInfections and infestations4/119
Fluid OverloadMetabolism and nutrition disorders4/119
HyperkalaemiaMetabolism and nutrition disorders4/119
SyncopeNervous system disorders4/119
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders4/119

Baseline characteristics

Enrolled Population

Age, Continuous
Age, Continuous(years)HEPLISAV-B®
Mean59.9 ± 13.22
Age, Continuous
Age, Continuous(years)HEPLISAV-B®
Median61.0 (22.0 to 87.0)
Age, Customized
Age, Customized(Participants)HEPLISAV-B®
18-5547
56+72
Sex: Female, Male
Sex: Female, Male(Participants)HEPLISAV-B®
Female47
Male72
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HEPLISAV-B®
Hispanic or Latino22
Not Hispanic or Latino97
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HEPLISAV-B®
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American61
White51
More than one race7
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)HEPLISAV-B®
United States119
Weight
Weight(kg)HEPLISAV-B®
Mean89.9 ± 24.93

8 further baseline measures are reported on the registry.

09

Study locations

20 sites
  • DaVita Clinical Research or Affiliate
    Bloomfield, Connecticut 06002, United States
  • DaVita Clinical Research or Affiliate
    Middlebury, Connecticut 06762, United States
  • DaVita Clinical Research or Affiliate
    Hollywood, Florida 33021, United States
  • DaVita Clinical Research or Affiliate
    Ocala, Florida 34471, United States
  • DaVita Clinical Research or Affiliate
    Tampa, Florida 33614, United States
  • DaVita Clinical Research or Affiliate
    Winter Park, Florida 32789, United States
  • DaVita Clinical Research or Affiliate
    Jeffersonville, Indiana 47130, United States
  • DaVita Clinical Research or Affiliate
    Roseville, Michigan 48066, United States
  • DaVita Clinical Research or Affiliate
    Edina, Minnesota 55435, United States
  • DaVita Clinical Research or Affiliate
    Minneapolis, Minnesota 55404, United States
  • DaVita Clinical Research or Affiliate
    Kansas City, Missouri 64111, United States
  • DaVita Clinical Research or Affiliate
    Las Vegas, Nevada 89106, United States
  • DaVita Clinical Research or Affiliate
    Bronx, New York 10461, United States
  • DaVita Clinical Research or Affiliate
    Asheville, North Carolina 28801, United States
  • DaVita Clinical Research or Affiliate
    Canton, Ohio 44718, United States
  • DaVita Clinical Research or Affiliate
    Philadelphia, Pennsylvania 19106, United States
  • DaVita Clinical Research or Affiliate
    El Paso, Texas 79902, United States
  • DaVita Clinical Research or Affiliate
    San Antonio, Texas 78229, United States
  • DaVita Clinical Research or Affiliate
    Norfolk, Virginia 23510, United States
  • DaVita Clinical Research or Affiliate
    Milwaukee, Wisconsin 53227, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Oct 2020, 18 months.

Results were first posted in Aug 2024, 3 years 9 months after primary completion.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 18 months is above that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2019
First posted
May 2, 2019
StartActual
Apr 22, 2019
Primary completionActual
Oct 23, 2020
CompletionActual
Sep 15, 2021
Results first posted
Aug 9, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03934736
Responsible party
Sponsor
First posted
May 2, 2019
Start date
Apr 22, 2019
Primary completion
Oct 23, 2020
Completion
Sep 15, 2021
Results posted
Aug 9, 2024
Last update
Aug 9, 2024

Study contacts

Robert Janssen, MD
study chair · Dynavax Technologies Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Heplisav-B

Start the discussion